stockrow
Friday 6 November 2026
Export BBIO’s income statement to Excel — free account
BridgeBio Pharma, Inc.
BBIO Healthcare Biotechnology
BridgeBio Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $502.1 million, up 126.3% from fiscal 2024.
- Revenue
- +192.6%
- EPS
- +67.5%
- Free cash flow
- +60.5%
- Total debt
- +4.21%
Quarter to September 2026, against a year earlier
74.28
0.01
+0.01%
Follow BBIO
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
3 | 4 | 4 | 4 |
| 41.03% | 36.94% | 32.31% | 26.22% | ||
| (78.14%) | (64.06%) | (60.23%) | (37.48%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(140.72%) | (167.85%) | (333.08%) | (55.21%) | |
Average Days of Receivables |
101.37 | 129.16 | 130.26 | 144.79 | |
Free Cash Flow per Share |
(2.38) | (2.29) | (2.22) | (1.89) | |
Free Cash Flow |
(455.55) | (445.12) | (435.39) | (369.80) | |
Capital Expenditures |
(9.64) | (1.17) | (1.01) | (0.83) | |
| Other line items | |||||
Cash ROIC |
(125.17%) | (74.39%) | (304.86%) | (20.37%) | |
Accounts Receivable Turnover |
6.97 | 3.62 | 4.30 | 3.85 | |
Accounts Payable Turnover |
0.91 | 1.00 | 1.49 | 1.00 | |
Inventory Turnover |
0.00 | 1.53 | 1.12 | 1.27 | |
Average Days of Payables |
630.82 | 375.28 | 250.38 | 601.66 | |
Days of Inventory on Hand |
465.84 | 425.93 | 486.38 | 407.10 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
90.02% | 80.55% | 70.87% | 56.69% | |
Selling, General and Administrative Expense of Revenue |
105.81% | 101.52% | 90.58% | 74.99% | |
Share Based Compensation of Revenue |
26.49% | 24.21% | 20.65% | 16.06% | |
Interest Coverage |
(2.94) | (2.78) | (2.42) | (1.71) | |
Operating CF/Net income |
0.62 | 0.62 | 0.63 | 0.62 | |
Depreciation/Fixed assets |
2.12 | 2.33 | 2.24 | 2.35 | |
Capex/Depreciation |
(0.85) | (0.10) | (0.09) | (0.07) | |
Revenue per Share |
2.62 | 2.98 | 3.64 | 4.82 | |
Operating CF per Share |
(2.33) | (2.28) | (2.22) | (1.88) | |
Capex per Share |
(0.05) | (0.01) | (0.01) | 0.00 | |
Capex to Sales |
0.02 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 6 Nov 2026